Skip to Content

Avastin Dosage

Generic name: bevacizumab 100mg in 4mL
Dosage form: injection, solution

Medically reviewed on June 19, 2018.

Important Administration Information

Do not administer Avastin until at least 28 days following surgery and the wound is fully healed.

Metastatic Colorectal Cancer (mCRC)

The recommended dose when Avastin is administered in combination with intravenous 5-fluorouracil-based chemotherapy is:

  • 5 mg/kg every 2 weeks intravenously in combination with bolus-IFL.
  • 10 mg/kg every 2 weeks intravenously in combination with FOLFOX4.
  • 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Avastin-containing regimen.

First-Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

The recommended dose is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel.

Recurrent Glioblastoma (GBM)

The recommended dose is 10 mg/kg intravenously every 2 weeks.

Metastatic Renal Cell Carcinoma (mRCC)

The recommended dose is 10 mg/kg intravenously every 2 weeks in combination with interferon alfa.

Persistent, Recurrent, or Metastatic Cervical Cancer

The recommended dose of Avastin is 15 mg/kg intravenously every 3 weeks in combination with paclitaxel and cisplatin or in combination with paclitaxel and topotecan.

Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Treatment of Stage III or IV Disease Following Initial Surgical Resection:

The recommended dose is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by Avastin 15 mg/kg every 3 weeks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs earlier.

Treatment of Recurrent Disease:

Platinum Resistant

The recommended dose is 10 mg/kg intravenously every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan (every week).

The recommended dose is 15 mg/kg intravenously every 3 weeks in combination with topotecan (every 3 weeks).

Platinum Sensitive

The recommended dose is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and paclitaxel for 6 to 8 cycles, followed by Avastin 15 mg/kg every 3 weeks as a single agent until disease progression.

The recommended dose is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and gemcitabine for 6 to 10 cycles, followed by Avastin 15 mg/kg every 3 weeks as a single agent until disease progression.

Dose Modifications for Adverse Reactions

Table 1 describes dose modifications for specific adverse reactions [see Warnings and Precautions (5)]. No dose reductions for Avastin are recommended.

Table 1: Dose Modifications for Adverse Reactions
Adverse Reaction Severity Dose Modification
Gastrointestinal Perforation and fistulae [see Warnings and Precautions (5.1)].
  • Gastrointestinal perforation, any grade
  • Tracheoesophageal fistula, any grade
  • Fistula, Grade 4
  • Fistula formation involving any internal organ
Discontinue Avastin
Wound Healing Complications [see Warnings and Precautions (5.2)].
  • Wound healing complications requiring medical intervention
  • Necrotizing fasciitis
Discontinue Avastin
Hemorrhage [see Warnings and Precautions (5.3)].
  • Grade 3 or 4
Discontinue Avastin
  • Recent history of hemoptysis of 1/2 teaspoon (2.5 mL) or more
Withhold Avastin
Thromboembolic Events [see Warnings and Precautions (5.4, 5.5)].
  • Arterial thromboembolism, severe
Discontinue Avastin
  • Venous thromboembolism, Grade 4
Discontinue Avastin
Hypertension [see Warnings and Precautions (5.6)].
  • Hypertensive crisis
  • Hypertensive encephalopathy
Discontinue Avastin
  • Hypertension, severe
Withhold Avastin if not controlled with medical management; resume once controlled
Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.7)].
  • Any
Discontinue Avastin
Renal Toxicity and Proteinuria [see Warnings and Precautions (5.8)].
  • Nephrotic syndrome
Discontinue Avastin
  • Proteinuria greater than or equal to 2 grams per 24 hours in absence of nephrotic syndrome
Withhold Avastin until proteinuria less than 2 grams per 24 hours
Infusion Reaction [see Warnings and Precautions (5.10)].
  • Severe infusion reaction
Discontinue Avastin
  • Clinically significant
Interrupt infusion; resume at a decreased rate of infusion after symptoms resolve
  • Mild, clinically insignificant
Decrease infusion rate
Congestive Heart Failure [see Warnings and Precautions (5.12)]. Any Discontinue Avastin

Preparation and Administration

Administration

  • Administer as an intravenous infusion.
  • First infusion: Administer infusion over 90 minutes.
  • Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated.

Preparation

  • Use appropriate aseptic technique.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
  • Withdraw necessary amount of Avastin and dilute in a total volume of 100 mL of 0.9% Sodium Chloride Injection, USP. DO NOT ADMINISTER OR MIX WITH DEXTROSE SOLUTION.
  • Discard any unused portion left in a vial, as the product contains no preservatives.
  • Store diluted Avastin solution at 2–8°C (36–46°F) for up to 8 hours.
  • No incompatibilities between Avastin and polyvinylchloride or polyolefin bags have been observed.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide